Cytomegalovirus glycoprotein vaccine - GlaxoSmithKline

Drug Profile

Cytomegalovirus glycoprotein vaccine - GlaxoSmithKline

Alternative Names: GSK 1492903A; GSK Biologicals' recombinant CMV gB vaccine

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Cytomegalovirus vaccines; Glycopeptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cytomegalovirus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cytomegalovirus infections(Prevention) in Belgium (IM, Injection)
  • 27 Jan 2012 GlaxoSmithKline re-initiates enrolment in a phase I trial in Healthy volunteers in Belgium (NCT01357915)
  • 22 Sep 2011 GlaxoSmithKline completes enrolment in its phase I trial in Healthy volunteers in Belgium (NCT01357915)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top